Macrovascular invasion (MVI) in patients with hepatocellular carcinoma (HCC) is associated with poor prognosis and limited therapeutic options. Here the authors report the results of a phase 2 trial of perioperative tislelizumab (anti-PD1) plus intensity modulated radiotherapy in resectable HCC with MVI.
- Hongyu Pan
- Liuyu Zhou
- Ruoyu Wang
